Clinical observation of a 64-year-old female patient with plasma cell leukemia diagnosed during coronavirus infection COVID-19

Cover Page

Cite item

Full Text

Abstract

Plasma cell leukemia (PCL) is a rare malignant plasma cell neoplasm with aggressive clinical progression, minimal response to therapy and unfavorable prognosis. Concomitant new coronavirus infection COVID-19 and its complications significantly worsen prognosis in patients with PCL. Currently, approaches to PCL therapy are not finalized, and regimens developed for multiple myeloma are used. In PCL, the most common clinical symptoms are renal failure and hypercalcinemia which are frequently observed in multiple myeloma. Therefore, use of proteasome inhibitor (bortezomib) with proven effectiveness in multiple myeloma, is justified. A clinical observation of a 64-year-old female patient who was hospitalized in poor physical condition with the new coronavirus infection COVID-19 is presented. During hospitalization, debut of PCL was suspected, and as soon as possible after diagnosis confirmation using vital indications, antitumor drug therapy was started with positive effect. 

About the authors

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816

Yulia E. Ryabukhina

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

O. L. Timofeeva

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6229-7300

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

Department of Oncology I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, 

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

F. M. Abbasbeyli

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-2359-0547

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

M. V. Antonets

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

V. E. Gruzdev

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-9454-0002

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

M. A. Anisimov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-4484-6716

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

A. A. Akhobekov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6395-5790

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

N. A. Kupryshina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-8509-0954

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

References

  1. Usmani S.Z., Nair B., Qu P. et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia 2012;26(11):2398–405. doi: 10.1038/leu.2012.107
  2. Gonsalves W.I., Rajkumar S.V., Go R.S. et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014;124(6):907–12. doi: 10.1182/blood-2014-03-565051
  3. Fernández de Larrea C., Kyle R.A., Durie B.G. et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27(4):780–91. doi: 10.1038/leu.2012.336
  4. Tiedemann R.E., Gonzalez-Paz N., Kyle R.A. et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22(5):1044–52. doi: 10.1038/leu.2008.4
  5. Van de Donk N.W., Lokhorst H.M., Anderson K.C., Richardson P.G. How I treat plasma cell leukemia. Blood 2012;120(12):2376–89. doi: 10.1182/blood-2012-05-408682
  6. Gowin K., Skerget Sh., Keats J.J. et al. Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res 2021;111:106687. doi: 10.1016/j.leukres.2021.106687
  7. Jurczyszyn A., Radocha J., Davila J. et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol 2018;180(6):831–9. doi: 10.1111/bjh.15092
  8. Jurczyszyn A., Castillo J.J., Avivi I. et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma 2019;60(1):118–23. doi: 10.1080/10428194.2018.1473574
  9. Chang H., Qi X., Yeung J. et al. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009;33(2):259–62. doi: 10.1016/j.leukres.2008.06.027
  10. Cazaubiel T., Buisson L., Maheo S. et al. The genomic and transcriptomic landscape of plasma cell leukemia. ASH Annual Meeting, 2020. Available at: https://ash.confex.com/ash/2020/webprogram/Paper139340.html
  11. Musto P., Simeon V., Martorelli M.C. et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014;28(1):222–5. doi: 10.1038/leu.2013.241
  12. Usmani S.Z., Hoering A., Ailawadhi S. et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 2021;8(1):e45–e54. doi: 10.1016/S2352-3026(20)30354-9
  13. Van De Donk N.V.D., van der Holt B., Schjesvold F.H. et al. Treatment of primary plasma cell leukemia with carfilzomib and lenalidomidebased therapy: results of the first interim analysis of the phase 2 EMN12/HOVON129 study. Blood 2019;134(Suppl 1):693. doi: 10.1182/blood-2019-125120
  14. Gowda L., Shah M., Badar I. et al. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 2019;54(7):1089–93. doi: 10.1038/s41409-018-0392-1
  15. Mahindra A., Kalaycio M.E., Vela-Ojeda J. et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012;26(5):1091–7. doi: 10.1038/leu.2011.312
  16. Cha C.H., Park C.J., Huh J.R. et al. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 2007;118(3):178–82. doi: 10.1159/000109470
  17. Katodritou E., Terpos E., Kelaidi C. et al. Treatment with bortezomibbased regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol 2014;89(2):145–50. doi: 10.1002/ajh.23600
  18. Jimenez-Zepeda V.H., Reece D.E., Trudel S. et al. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leuk Lymphoma 2015;56(1):232–5. doi: 10.3109/10428194.2014.893304
  19. Neben K., Lokhorst H.M., Jauch A. et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4): 940–8. doi: 10.1182/blood-2011-09-379164
  20. Avet-Loiseau H., Leleu X., Roussel M. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28(30):4630–4. doi: 10.1200/JCO.2010.28.3945
  21. D’Arena G., Valentini C.G., Pietrantuono G. et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012;23(6):1499–502. doi: 10.1093/annonc/mdr480
  22. Esparís-Ogando A., Alegre A., Aguado B. et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005;114(4):665–7. doi: 10.1002/ijc.20793
  23. Finnegan D.P., Kettle P., Drake M. et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006;47(8):1670–3. doi: 10.1080/10428190500520954
  24. Libby E., Candelaria-Quintana D., Moualla H. et al. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 2010;85(9):733–4. doi: 10.1002/ajh.21790
  25. Grassinger J., Südhoff T., Andreesen R., Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85(2):132–3. doi: 10.1007/s00277-005-0027-7
  26. Wang H., Zhou H., Zhang Z. et al. Bortezomib-based regimens improve the outcome of patients with primary or secondary plasma cell leukemia: a retrospective cohort study. Turk J Haematol 2020;37(2):91–7. doi: 10.4274/tjh.galenos.2019.2019.0254
  27. Musto P., Rossini F., Gay F. et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007;109(11):2285–90. doi: 10.1002/cncr.22700
  28. Chudnova T.S., Baryakh E.A., Litvinenko M.S. et al. Chemotherapy of hematological malignancies in patients with COVID-19. Oncohematology 2022;17(2):107–20. (In Russ.). doi: 10.17650/1818-8346-2022-17-2-107-120
  29. Passamonti F., Cattaneo C., Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7(10):e737–45. doi: 10.1016/S2352-3026(20)30251-9
  30. Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 2021;7(2):220–7. doi: 10.1001/jamaoncol.2020.6178
  31. Grivas P., Khaki A.R., Wise-Draper T.M. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021;32(6):787–800. doi: 10.1016/j.annonc.2021.02.024
  32. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(4):844–7. doi: 10.1111/jth.14768
  33. Lebedeva A.A., Kulikov A.N., Kovalchuk I.P. et al. Endothelial dysfunction and thrombotic events in patients with severe novel coronavirus infection COVID-19. Ucheniye zapiski SPbGMU im. akad. I.P. Pavlova = The Scientific Notes of the Pavlov University 2021;28(4):38–47. (In Russ.). doi: 10.24884/1607-4181-2021-28-4-38-47
  34. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7. doi: 10.1016/j.thromres.2020.04.013
  35. Miesbach W., Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost 2020;26:1076029620938149. doi: 10.1177/1076029620938149

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.